---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-031010"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T03:20:11.003614+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rigel Q4 net income $0.7M; TAVALISSE sales $25.7M (+17% YoY); acquires GAVRETO rights

## Summary
- Q4 total revenue $35.8M, TAVALISSE net sales $25.7M (+17% YoY), REZLIDHIA net sales $3.9M (+333% YoY).
- FY 2023 net loss $25.1M ($0.14/sh) vs $58.6M in 2022; revenue $116.9M, TAVALISSE $93.7M (+24% YoY).
- Acquired U.S. rights to GAVRETO (pralsetinib) for RET+ NSCLC/thyroid cancer; expects sales recognition in Q3 2024.
- Q4 TAVALISSE bottles shipped to patients/clinics: 2,463; REZLIDHIA bottles: 278 direct, QoQ growth 47%.
- Cash & short-term investments $56.9M at Dec 31, 2023, vs $58.2M at Dec 31, 2022.

## SEC filing metadata
- accession: 0001104659-24-031010
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465924031010/0001104659-24-031010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465924031010/tm247928d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-031010
- JSON: https://secwatch.observer/filing/0001104659-24-031010.json
- Plain text: https://secwatch.observer/filing/0001104659-24-031010.txt

## Key facts
- Earnings Releases
  RIGEL PHARMACEUTICALS INC reported financial results for fourth quarter and full year ended December 31, 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On March 5, 2024, Rigel Pharmaceuticals, Inc. (“ Rigel ”) announced certain financial results for its fourth quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465924031010/0001104659-24-031010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.